CDK4 and breast cancer: Finally, to evaluate whether targeting OXPHOS could be effective in metastatic BC showing primary resistance to CDK4/6 inhibitors, we established two PDX from BM of patients treated with first-line palbociclib plus letrozole (Fig. 3C).